PSMA-PET: aanwinst voor de prostaatkankerdiagnostiek

Publication date

2023-01-04

Authors

van der Sar, Esmée
Lavalaye, Jules
Braat, A. J.A.T.ORCID 0000-0002-8824-8697
de Klerk, John M.H.
Lam, MarnixORCID 0000-0002-4902-9790
de Keizer, BartORCID 0000-0002-6270-9483ISNI 0000000393842428

Editors

Advisors

Supervisors

DOI

Document Type

Article

Collections

Open Access logo

License

taverne

Abstract

SMA PET/CT is a diagnostic technique for patients with prostate cancer. It makes use of a radioligand that specifically binds to 'prostate specific membrane antigen' (PSMA), expressed by the prostate cancer cells. PSMA PET has proven to be highly effective in prostate cancer diagnostics in both primary staging and re-staging. PSMA PET/CT has a much higher accuracy than traditional CT and skeletal scintigraphy for the detection of metastases, allowing metastases to be detected in an earlier stage. The clinical relevance of the improved detection is now under investigation. Staging with PSMA PET/CT sometimes leads to avoiding surgery because distant metastases are found that were not detected with conventional imaging. In the Netherlands, PSMA PET/CT is now indicated both in primary prostate cancer diagnostics for the detection of metastases and for the detection of biochemical recurrence after prostatectomy or after radiotherapy.

Keywords

Taverne, General Medicine

Citation

van der Sar, E C A, Lavalaye, J, Braat, A J A T, de Klerk, J M H, Lam, M G E H & de Keizer, B 2023, 'PSMA-PET : aanwinst voor de prostaatkankerdiagnostiek', Nederlands Tijdschrift voor Geneeskunde, vol. 167, no. 2, D6950. < https://www.ntvg.nl/artikelen/psma-pet-aanwinst-voor-de-prostaatkankerdiagnostiek >